Locating Novel Paget's Loci by Tumor Allelotyping

描述(来自申请者的逐字)：佩吉氏骨病是 仅次于骨质疏松症的第二大常见的骨代谢疾病。它导致了 快速的骨骼形成，改变骨骼的强度和形状。 在一些家族中，佩吉特氏病的易感性与 染色体1 8q.然而，最近的证据表明，倾向于 Paget病是遗传异质性的，两个或更多的基因座必须是 与家族性Paget病的易感性有关。骨肉瘤是一种罕见的 Paget病的严重并发症。我们实验室已经鉴定出一种 Paget病与骨肉瘤的关系分析了这两个零星的 Paget病患者的骨肉瘤和骨肉瘤被揭示 这些肿瘤经历了肿瘤特有的结构杂合性丢失 (LOH)在一个与佩吉特氏病的易感性密切相关的地区。 这表明，一些与肿瘤发生有关的基因 骨肉瘤也可能与Paget病的易感性有关。那里 这项提案有三个目标。第一个是识别额外的基因 容易患上佩吉特氏病的人。我们计划利用我们独特的 收集Pagtic骨肉瘤以等位基因分析正常人、 Pagtic骨肉瘤患者的页状骨和肿瘤样本 确定可能包含新的肿瘤抑制基因的区域，这些基因涉及 传教或致瘤过程。然后可以对这些候选区域进行测试 18q染色体上与家族性Paget病的连锁-未连锁Paget‘s 以确定这些新的肿瘤抑制基因中是否有任何一个可以 代表Paget的其他易感基因座。我们有可能会 用这种方法找不到与Paget病易感性有关的基因。在……里面 在这种最坏的情况下，我们仍然会实现我们的第二个目标，即 描述Pagtic骨肉瘤中发生的遗传事件，并 将它们与散发性骨肉瘤中发生的遗传事件进行比较。 这将使我们能够确定这两种疾病是否具有共同的基因 起源。此外，通过在我们的分析中包括页面状骨骼，我们将能够 实现我们的第三个目标，即确定是否存在起作用的基因 在散发性Paget‘s病的发病中以肿瘤抑制因子样的方式出现。 综上所述，这些分析将使我们能够检查 家族性Paget病的分子遗传学特征 寻常型骨肉瘤和散发性Paget病。

DESCRIPTION (Verbatim from the Applicant): Paget's Disease of bone is the second most common metabolic disease of bone after osteoporosis. It results in rapid bone formation, altering the strength and shape of the bone. Predisposition to Paget's Disease has been linked in some families to chromosome 1 8q. However, recent evidence has shown that predisposition to Paget's Disease is genetically heterogeneous and that two or more loci must be involved in familial Paget's Disease predisposition. Osteosarcoma is a rare but serious complication of Paget's Disease. Our laboratory has identified an association between Paget's Disease and osteosarcoma. Analysis of both sporadic osteosarcomas and osteosarcomas from patients with Paget's Disease revealed that these tumors undergo tumor-specific loss of constitutional heterozygosity (LoH) in a region that is tightly linked to predisposition to Paget's Disease. This suggests that some of the genes that are involved in tumongenesis of osteosarcomas may also be involved in predisposition to Paget's Disease. There are three goals for this proposal. The first is to identify additional genes that predispose to Paget's Disease. We propose to take advantage of our unique collection of pagetic osteosarcomas to allelotype the entire genomes of normal, pagetoid bone, and tumor samples from patients with pagetic osteosarcoma to identify regions that may harbor novel tumor suppressor loci involved in either the pagetic or tumongenic process. These candidate regions can then be tested for linkage to familial Paget's Disease in chromosome 18q-unlinked Paget's families to determine if any of these novel tumor suppressor genes may represent additional Paget's predisposition loci. It is possible that we will not find genes involved in predisposition to Paget's Disease by this method. In this worst-case scenario, we will still realize our second goal, which is to characterize the genetic events that take place in pagetic osteosarcoma and to compare them to the genetic events that take place in sporadic osteosarcoma. This will allow us to determine whether these two diseases share common genetic origins. Further, by including pagetoid bone in our analysis we will be able to realize our third goal, which is to determine whether there are genes which act in a tumor suppressor-like fashion in the onset of sporadic Paget's Disease. Together, these analyses will allow us to examine both the predisposition to familial Paget's Disease, as well as to characterize the molecular genetics of pagetic osteosarcoma and sporadic Paget's Disease.